Douglas J. Eleveld

Dr. Douglas J. Eleveld


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
DEDouglas J. Eleveld
Douglas J. Eleveld
PCP. Colin
P. Colin
AAA.R. Absalom
A.R. Absalom
MSM.M.R.F. Struys
M.M.R.F. Struys

1 June 2014 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
DEDouglas J. Eleveld
Douglas J. Eleveld
JPJohannes H. Proost
Johannes H. Proost
LCLuis I. Cortínez
Luis I. Cortínez
AAAnthony R. Absalom
Anthony R. Absalom
MSMichel M. R. F. Struys
Michel M. R. F. Struys
Patient groups or anesthetic techniques, and there is uncertainty of the accuracy of the models under differing patient and clinical conditions. Our goal was to determine a PK model with robust predictive performance for a wide range of patient groups and clinical conditions. METHODS: We aggregated and analyzed 21 previously published propofol datasets containing data from young children, children, adults, elderly, and obese individuals. A 3-compartmental allometric model was estimated with NONMEM software using weight, age, sex, and patient status as covariates. A predictive performance metric focused on intraoperative conditions was devised and used along with the Akaike information criteria to guide model development. RESULTS: The dataset contains 10,927 drug concentration observations from 660 individuals (age range 0.25–88 years; weight range 5.2–160 kg). The final model uses weight, age, sex, and patient versus healthy volunteer as covariates. Parameter estimates for a 35-year, 70-kg male patient were: 9.77, 29.0, 134 L, 1.53, 1.42, and 0.608 L/min for V1, V2, V3, CL, Q2, and Q3, respectively. Predictive performance is better than or similar to that of specialized models, even for the subpopulations on which those models were derived. CONCLUSIONS: We have developed a single propofol PK model that performed well for a wide range of patient groups and clinical conditions. Further prospective evaluation of the model is needed....

1 October 2020 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
DEDouglas J. Eleveld
Douglas J. Eleveld
PCPieter Colin
Pieter Colin
AAAnthony R. Absalom
Anthony R. Absalom
MSMichel M.R.F. Struys
Michel M.R.F. Struys

21 July 2025 in Clinical Pharmacokinetics
Verified
Journal Article
Open access
PDF file
BJBas T. de Jong
Bas T. de Jong
DEDouglas J. Eleveld
Douglas J. Eleveld
KMKeira Mason
Keira Mason
MSMichel MRF Struys
Michel MRF Struys
Remimazolam is a benzodiazepine with a high affinity for the γ-aminobutyric acid type A-receptor thereby inducing sedation and amnesia. It is a short-acting drug, has a fast onset, short duration of action, and a predictable recovery profile. Remimazolam is metabolized mainly into CNS7054. In recent years, numerous population pharmacokinetic and combined pharmacokinetic/pharmacodynamic studies have been published. This narrative review aims to give an overview of and insight into pharmacokinetic/pharmacodynamic models and related clinical effects. Body weight, age and American Society of Anesthesiologists classification, sex, hepatic function, and extracorporeal circulation have been shown to significantly impact remimazolam pharmacokinetics. Body mass index, race, concomitant opioid administration, and a CNS7054-induced tolerance effect may be covariates. The labeling of remimazolam is not consistent worldwide as it has been approved for general anesthesia and/or sedation in different countries. To date, remimazolam is only approved by the intravenous route. Remimazolam has been approved for general anesthesia and/or sedation. The incidence of postoperative nausea and vomiting seems higher compared with propofol, yet pain on injection is less common. One study has published population pharmacokinetics in children. Reports on alternative methods to intravenous administration have been sparse.

30 April 2025 in British Journal of Anaesthesia
Verified
Journal Article
Open access
DEDouglas J. Eleveld
Douglas J. Eleveld
PCPieter J. Colin
Pieter J. Colin
JBJohannes P. Van Den Berg
Johannes P. Van Den Berg
JKJeroen V. Koomen
Jeroen V. Koomen
TSThomas Stoehr
Thomas Stoehr
MSMichel M.R.F. Struys
Michel M.R.F. Struys
Pharmacokinetic-pharmacodynamic (PK-PD) models of remimazolam and their covariate relationships are useful for understanding drug disposition and predicting drug effects. Although clinical studies have shown that remimazolam induction doses decline with advancing age, this property is not reflected in existing models. The purpose of this investigation was to develop a PK-PD model for remimazolam and perform covariate analysis to maximise its utility across broad, diverse populations and to evaluate its consistency with clinical observations of drug dosing. Arterial and venous concentrations of remimazolam and its metabolite, Modified Observer's Assessment of Alertness and Sedation score and bispectral index were determined in 20 studies. Final population models were developed with covariate analysis. Simulations of drug administration for sedation and anaesthesia for this and previously published models were compared with the results of clinical studies. Model development proceeded from 933 individuals aged 6-93 yr and weight 21-171 kg. PK data from studies with extracorporeal membrane oxygenation and treatment in ICU were considered in a post hoc analysis. Simulations of target-controlled infusion with the final model targeting sedation (Modified Observer's Assessment of Alertness and Sedation score 2 or 3) or anaesthesia (bispectral index 50) showed drug administration declining with age consistent with clinical observations. A PK-PD model for remimazolam was developed for a broad, diverse population. Dosing and target concentrations are proposed that are clinically useful for anaesthesia and sedation, especially for target-controlled infusion administration.

2 February 2022 in Anesthesiology
Verified
Journal Article
Closed access
PDF file
DEDouglas J. Eleveld
Douglas J. Eleveld
JKJeroen V. Koomen
Jeroen V. Koomen
AAAnthony R. Absalom
Anthony R. Absalom
HSHong Su
Hong Su
LHLaura N. Hannivoort
Laura N. Hannivoort
MSMichel M. R. F. Struys
Michel M. R. F. Struys
A clinical review is presented of basic allometric scaling theory and its application to pharmacokinetic models in anesthesia and other fields in the biologic sciences.